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Hypothalamic fatty acid metabolism is involved in CNS controls of feeding and energy balance. Malonyl-
CoA, an intermediate of fatty acid biosynthesis, is emerging as a significant player in these processes. 
Notably, hypothalamic malonyl-CoA has been implicated in leptin’s feeding effect. Leptin treatment 
increases malonyl-CoA level in the hypothalamic arcuate nucleus (Arc), and this increase is required for 
leptin-induced decrease in food intake. However, the intracellular downstream mediators of malonyl-
CoA's feeding effect have not been identified. A primary biochemical action of malonyl-CoA is the 
inhibition of the acyltransferase activity of carnitine palmitoyltransferase-1 (CPT-1). In the hypothalamus, 
the predominant isoform of CPT-1 that possesses the acyltransferase activity is CPT-1 liver type (CPT-
1a). To address the role of CPT-1a in malonyl-CoA's anorectic action, we used a recombinant adenovirus 
expressing a mutant CPT-1a that is insensitive to malonyl-CoA inhibition. We show that arcuate nucleus 
overexpression of the mutant CPT-1a blocked the malonyl-CoA-mediated inhibition of CPT-1 activity. 
However, the overexpression of this mutant did not affect the anorectic actions of leptin or central 
cerulenin for which an increase in Arc malonyl-CoA level is also required. Thus, CPT-1a does not appear 
to be involved in the malonyl-CoA's anorectic actions induced by leptin. Furthermore, long-chain fatty 
acyl-CoA’s, substrates of CPT-1a, dissociate from malonyl-CoA’s actions in the Arc under different 
feeding states. Together, our results suggest that Arc intracellular mechanisms of malonyl-CoA's 
anorectic actions induced by leptin are independent of CPT-1a. The data suggest that target(s) rather 












Obesity is a major health problem and a major cause of insulin-resistance and diabetes. An imbalance 
between energy intake and energy expenditure can lead to overweight and contribute to the development 
of obesity and the metabolic syndrome. The hypothalamus plays a critical role in the CNS control of 
feeding and energy balance (21, 28). A large body of evidence now shows that fatty acid metabolism 
participates in this action of the hypothalamus (1, 3, 5-7, 9, 11, 12, 15, 17, 18, 20, 23, 24). In this regard, 
malonyl-CoA, an intermediate in fatty acid biosynthesis, is emerging as a significant player in the 
hypothalamic control of feeding and body energy balance (5-7, 9, 11, 12, 15, 18), Recent data have 
linked malonyl-CoA signaling action to the hypothalamic intracellular pathways of leptin in the central 
regulation of energy balance (6, 9). In the hypothalamus, leptin treatment increases malonyl-CoA level via 
inhibiting AMP-activated protein kinase (AMPK) and activating acetyl-CoA carboxylase (ACC) (2, 6). 
Notably, the increase of hypothalamic malonyl-CoA induced by leptin takes place specifically in the 
arcuate nucleus (Arc) (6), a critical site in mediating leptin’s central actions on feeding and energy 
balance (28). Despite these findings, the intracellular mechanisms by which malonyl-CoA impacts feeding 
remain unclear. It is known that malonyl-CoA inhibits the acyltransferase activity of carnitine 
palmitoyltransferase-1 (CPT-1) that converts long-chain fatty acyl-CoA (LCFA-CoA) to long chain 
acylcarnitine (9, 23). CPT-1 has liver- and muscle-isoforms, with the hypothalamus mainly expressing the 
liver-isoform (CPT-1a) (23). Pharmacological studies have demonstrated that ICV administration of 
compound ST-1326, a specific CPT-1a inhibitor, inhibits Arc CPT-1a activity, increases cellular LCFA-
CoA's levels, and reduces food intake (23). Accumulation of hypothalamic LCFA-CoA's has been 
suggested to have anorectic effects as ICV oleic acid (which can form LCFA-CoA’s in cells) was shown to 
reduce food intake (24). Given that malonyl-CoA is a physiological inhibitor of CPT-1, inhibition of Arc 
CPT-1a and the ensuing increase of LCFA-CoA's have been proposed to mediate malonyl-CoA's 
anorectic signaling actions. However, a growing body of evidence now strongly challenges this 
hypothesis (16). For example, we previously demonstrated that exogenous leptin upregulates malonyl-
CoA level without affecting the level of LCFA-CoA's in the Arc (6). The result thus casts doubt on the role 
of CPT-1a as a mediator of malonyl-CoA's action in leptin feeding pathways. To clarify the role of CPT-1a 
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in the Arc, we used a recombinant adenovirus expressing a mutant CPT-1a that is insensitive to malonyl-
CoA inhibition (10). Using this mutant, we examined the feeding responses of the animals with a 





























Animal preparations for feeding experiments: Animal experiments were performed in accordance with 
the guidelines of the Canadian Council for Animal Care, and were approved by the University of Alberta 
Animal Policy and Welfare Committee.  Male Sprague–Dawley rats (225–300 g) were purchased from 
Charles River Laboratories. The rats were housed in a controlled (12h light/12h dark) environment, and 
were allowed ad. lib. access to standard laboratory chow and water unless otherwise noted. Before the 
feeding experiments were started, the rats were handled daily and subjected to mock injections to 
minimize the stress from the experimental manipulation. In the leptin study, leptin or vehicle was 
administered at 1h before the dark onset. Food intakes at 3h and 23h (overnight) after the dark onset 
were monitored. Overnight body weight changes (24h after the injection) were also monitored. In the 
cerulenin study, at 5h before the dark onset, food was removed. Then, cerulenin or vehicle was 
administered and food was not provided until the dark onset. Food intakes were monitored at 3h and 19h 
(overnight) after dark onset. Overnight body weight changes (24h after the injection) were also monitored. 
 
Brain sample preparations: At the designated time points, rats were euthanized by decapitation. Brains 
were rapidly dissected (within 1 min) and coronal brain sections were prepared using a cryostat or a brain 
matrix (Roboz Surgical Instrument, Maryland). Individual hypothalamic nuclei including arcuate nucleus 
(Arc), ventromedial nucleus (VMN), lateral hypothalamic area (LHA) and paraventricular nucleus (PVN) 
were dissected according to the established protocol (6). The accuracy of the dissection was verified by 
comparing the characteristic neuropeptide mRNA levels as detailed previously (6). 
 
Recombinant adenoviruses:  The adenoviruses were delivered into the Arc (1×107 p.f.u. / μl; 0.4μl per 
side) by bilateral stereotaxic injection (6). The coordinates were: anterior–posterior: -2.8 mm; dorsal–
ventral: -9.5 mm; and medial–lateral: ±0.4 mm. The accuracy of the injections was confirmed by 
histological analysis as described previously (6). The adenovirus encoding MCD contains the full length 
human MCD (hMCD) coding sequence (27). The adenovirus encoding the wild type CPT-1a contains the 
nucleotide sequence (58-2700) including the entire coding region of rat CPT1a and the same sequence 
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was used to generate the mutant CPT-1a with the 593-methionine residual mutated to serine residual 
(22). The feeding experiments with leptin and cerulenin were conducted in the second week following the 
initial delivery of the adenoviruses. Significantly high levels of protein expressions or enzyme activities 
were reliably detected after one week and these high levels last until at least fourteen days (two weeks) 
following the delivery of the viruses. 
 
Cannulation surgery and intracerebroventricular injection:  Cannulas were implanted into either the 
lateral or 3rd ventricle based on the established protocol (6). The accuracy of placement was confirmed 
by angiotensin-2 drinking test or histological analysis as previously described (6). After surgery, daily food 
intake and body weight were monitored. After body weights returned to the levels before surgery and the 
rats were fully habituated to the experimental manipulations, bolus injections of the chemicals (leptin and 
cerulenin) were administered ICV. 
 
Chemicals:  Leptin was obtained from A. F. Parlow, National Hormone and Pituitary Program, National 
Institute of Diabetes and Digestive and Kidney Diseases (USA). For ICV injection, a dose of 15μg of leptin 
dissolved in PBS was chosen based on our previous studies (6). Cerulenin was obtained from Sigma (St. 
Louis, MO) and 125μg in 25% DMSO/75% PBS (vehicle) was used in ICV injection as previously 
described (1).  
 
Quantifications of malonyl-CoA, long-chain fatty acyl-CoA’s and long-chain acylcarnitines: The 
CoA recycling assay was performed to measure the malonyl-CoA level and high performance liquid 
chromatography (HPLC) was used to measure the levels of long-chain acyl-CoA’s (consisting of 
palmitoyl-CoA, oleoyl-CoA and stearoyl-CoA) as detailed elsewhere (6). To measure the levels of the 
long-chain acylcarnitines, brain tissues were extracted with acetonitrile and 2-propanol (6). The extracts 
were dried under streams of nitrogen and were reconstituted in 300 μl acetonitrile and n-butanol (1:1). 
The samples were then filtered and loaded into HPLC coupled with mass spectrometer (13). The levels of 
long-chain acylcarnitines (consisting of palmitoylcarnitine, oleoylcarnitine and stearoylcarnitine) were 
quantitated as detailed before (13). 
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Malonyl-CoA decarboxylase (MCD) activity assay:  Adenovirus encoding human MCD or GFP (null) 
was stereotaxically delivered into the Arc. Individual hypothalamic nuclei (Arc, VMN, LHA and PVN) were 
dissected from coronal brain sections. The MCD activity assay was performed based on established 
protocol (6, 27).  
  
Carnitine palmitoyltransferase-1 (CPT-1) activity assay: The brain was removed from the skull within 
40 seconds and was immediately sectioned using the brain matrix. The mediobasal hypothalamic area 
(MBH), LHA and PVN were quickly dissected on ice and the tissues were immediately homogenized in 
the cold lysis buffer (0.25M sucrose, 5mM Tris-HCl and 1mM EGTA, pH 7.4). The crude homogenate was 
centrifuged at 800g for 10 minutes at 4°C. The resulting pellet was washed by resuspension in 2 volumes 
of the lysis buffer and was then centrifuged at 800g. This step was repeated twice to maximize the yield 
of the mitochondrial fraction. The combined supernatant was centrifuged at 6000g for 15 minutes at 4°C. 
The resulting pellet (crude mitochondrial fraction) was gently resuspended in the lysis buffer and was 
used in the activity assay using a radiometric method (20). 
 
Antibodies and Western blotting: The CPT-1a antibody (Ab) was generated as described elsewhere 
(29). Actin (Santa Cruz Biotechnology, Santa Cruz, CA) was used as the loading control in the Western 
blots. The procedures of protein electrophoresis, transfer and Ab detection were performed based on 
standard Western protocol (Invitrogen, California). Densitometry was performed using Scion Image 
software (Scion, Frederick, MD).  
 
Statistical analysis: Data are reported as means with SE. Data consisting of two groups were analyzed 
by Student t-test. Data consisting of three groups were analyzed by One-way ANOVA. These One-way 
ANOVAs, when they yielded significant overall effects, were further analyzed by Newman-Keuls Multiple 
Comparison Test for group comparisons. Data consisting of four or six groups were analyzed by Two-way 
ANOVA. These Two-way ANOVAs, when they yielded significant overall effects, were further analyzed by 





The M593S CPT-1a mutant is insensitive to malonyl-CoA inhibition.   In this study, we used a M593S 
CPT-1a mutant to address the role of CPT-1a in malonyl-CoA-mediated anorectic actions. The M593S 
mutation results in an impaired interaction between malonyl-CoA and the malonyl-CoA binding site in 
CPT-1a (22). We first verified malonyl-CoA insensitivity of this mutant using yeast cells that do not 
possess endogenous CPT-1 acyltransferase activity (22). We transfected yeast cells with the vector that 
expresses this mutant (CPT-1a mt) or the wild type CPT-1a (CPT-1a wt), and then measured CPT-1 
acyltransferase activity using the extracts from these cells. We found that malonyl-CoA inhibitory effect on 
the mutant was nearly abolished (Fig. 1A). Next, we evaluated CPT-1 acyltransferase activities in the 
hypothalamus. The adenovirus encoding the mutant CPT-1a (CPT-1a mt), the wild type CPT-1a (CPT-1a 
wt), or the null virus was delivered bilaterally into the Arc. Two weeks following delivering the viruses, rats 
were euthanized and CPT-1a protein levels were quantified in individual hypothalamic nuclei (Arc, VMN, 
LHA and PVN). Compared to the rats injected with the null adenovirus, CPT-1a (wt or mt) adenoviral 
infections induced increases in CPT-1a protein levels in the Arc while the CPT-1a protein levels were not 
altered in the VMN, LHA or PVN (Fig. 1B). Concomitant with the increased protein levels, CPT-1 
acyltransferase activities were also increased selectively in the mediobasal hypothalamic area (MBH) 
encompassing the Arc (Fig. 1C). Together, these data demonstrate Arc-specific overexpressions of CPT-
1a as well as activations of CPT-1 following the stereotaxic Arc delivery of the viruses. We then evaluated 
the response of CPT-1a to exogenous malonyl-CoA. We prepared crude mitochondrial extract from the 
mediobasal hypothalamic (MBH) region of the animals with Arc overexpressing the wild type CPT-1a or 
the mutant CPT-1a. Exogenous malonyl-CoA (50 µM) (20) was then added to the extracts and CPT-1 
activity assay was conducted. As expected, we observed that the mutant CPT-1a was resistant to the 
inhibitory effect of malonyl-CoA (Fig. 1D).    
 
Increase in Arc malonyl-CoA is required for leptin’s anorectic actions.   Before addressing the role 
of CPT-1a in leptin's malonyl-CoA signaling pathway, we confirmed the importance of malonyl-CoA in the 
central control of feeding and in leptin’s anorectic actions. The adenovirus encoding malonyl-CoA 
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decarboxylase (Ade-MCD) (27), which lowers malonyl-CoA level (9), was administered into the Arc of 
rats. Consistent with the previous finding (9), Arc delivery of the Ade-MCD increased daily food intakes 
and body weight gains, compared to the rats treated with the null virus (Fig. 2A). Delivery of the Ade-MCD 
induced an increase in MCD activity in the Arc (Fig. 2B), while the MCD activity was not altered in the 
VMN (Fig. 2B) or in the LHA and PVN (LHA: MCD, 87 ± 4.7 % vs. null, 100 ± 13 %; PVN: MCD, 105 ± 1 
% vs. null, 100 ± 10 %). In addition, following the delivery of the Ade-MCD, the malonyl-CoA level in the 
Arc was reduced (Fig. 2C). We then administered (ICV) leptin to the rats with Arc-specific activation of 
MCD. As we demonstrated in the previous study (6), leptin treatment increased malonyl-CoA level in the 
Arc (leptin: 220%, PBS: 100%; P<0.05). We further showed that the MCD overexpression attenuated the 
level of the increase in malonyl-CoA and antagonized the anorectic actions by leptin treatment (Fig. 2D). 
These results confirm that the increase in Arc malonyl-CoA level is a significant contributor to leptin’s 
anorectic effects. 
 
Blocking malonyl-CoA inhibition of CPT-1 acyltransferase activity does not affect leptin's 
anorectic actions.   We injected the adenovirus encoding wild type CPT-1a (Ade-CPT-1a wt), the mutant 
CPT-1a (Ade-CPT-1a mt) or the null (Ade-null) into the Arc of rats. Three to four days following the virus 
infections, daily food intakes and body weights returned to the pre-injection levels. At least through the 
eighth day following the initial injection of the viruses, no significant body weight or feeding differences 
were found among these rats (data not shown). We then assessed the role of malonyl-CoA inhibition of 
CPT-1 in leptin's anorectic actions. During the second week following the initial delivery of the viruses 
(around the eleventh day), leptin was injected to the rats. We found that Arc overexpression of CPT-1a mt 
(malonyl-CoA insensitive) did not affect leptin-induced feeding inhibition or weight loss (Fig. 3A). During 
this period (the second week following the injection of the viruses), the adenoviral infections did not affect 
the daily (24h) food intakes as compared to the basal pre-injection levels, and as in the first week 
described above, no significant differences of 24h food intakes were found among all treated groups 
(basal level: 100 ± 3.2 %, Ade-null: 103 ± 2.0 %, Ade-CPT-1a wt: 97 ± 2.1 %, Ade- CPT-1a mt: 95 ± 5.8 
%). Concomitant with producing similar anorectic effects, leptin induced similar increases in Arc malonyl-
CoA levels in all treated groups (Fig. 3B). Since malonyl-CoA inhibition of CPT-1 acyltransferase activity 
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is reversible (22), the CPT-1 activity assay using tissue extract is not informative in evaluating the in vivo 
effect of malonyl-CoA on CPT-1 activity. CPT-1 acyltransferase activity converts long-chain fatty acyl-
CoA’s (LCFA-CoA’s) to long-chain acylcarnitines (LC-AC’s) (13). We therefore assessed CPT-1a activity 
by measuring the levels of LC-AC’s. As expected, activation of Arc CPT-1a increased LC-AC’s levels in 
the Arc (Fig. 3C). Leptin reduced LC-AC’s levels in the Arc that ectopically expresses the wild type CPT-
1a (Fig. 3C), indicating an inhibition of CPT-1 activity by leptin in these animals. In contrast, leptin did not 
affect LC-AC’s levels in the Arc overexpressing the mutant CPT-1a (Fig. 3C), suggesting that leptin-
induced accumulation of malonyl-CoA does not inhibit the CPT-1 activities in these animals. In parallel 
with the changes in the levels of LC-AC’s, levels of total LCFA-CoA’s (substrates for CPT-1a) were 
reduced by CPT-1a activation (Fig. 3D). Leptin induced the increase in LCFA-CoA’s levels in the Arc 
ectopically expressing CPT-1a wt, while it did not affect LCFA-CoA’s levels in the Arc overexpressing the 
CPT-1a mt  (Fig. 3D). It should be noted that these biochemical assays were performed at the time when 
the feeding experiment with leptin was conducted (i.e. in the second week following viral injections). We 
also demonstrated (Fig. 1) that the effect of overexpressing the mutant CPT-1a on antaganizing malonyl-
CoA-mediated inhibition remained significant at a later time point (i.e. two weeks following the viral 
injections). Thus, we demonstrated that during the period when the leptin-induced inhibition of CPT-1a 
were blocked, the leptin-induced feeding inhibition was not affected. Taken together, these data 
demonstrate that blocking malonyl-CoA inhibition of CPT-1a and the resulting increase in LCFA-CoA’s 
level does not affect leptin’s anorectic actions. 
 
Blocking malonyl-CoA inhibition of CPT-1 acyltransferase activity does not affect the anorectic 
action of central cerulenin. To assess the role of CPT-1a in the specific context of malonyl-CoA 
signaling actions, we examined the feeding response to central cerulenin that is an inhibitor of fatty acid 
synthase (FAS). FAS uses malonyl-CoA as a substrate and blocking FAS activity increases malonyl-CoA 
level (15). We first show that overexpressing MCD attenuated the level of cerulenin-induced increase in 
Arc malonyl-CoA, and blocked the feeding inhibition induced by cerulenin treatment (Fig. 4A). These data 
demonstrate that an increase in Arc malonyl-CoA level is required for cerulenin’s anorectic effects. As 
expected, Arc overexpression of CPT-1a mt did not affect the anorectic effects by cerulenin, and 
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cerulenin treatment increased Arc malonyl-CoA to a similar level in all treated groups (Fig. 4B). It should 
be noted that the inhibition of FAS reduces the synthesis of long-chain fatty acids/acyl-CoA’s (14), which 
would contribute to lowering the LC-AC's levels via mass action. As a result, we did not monitor the CPT-
1 activity following cerulenin treatment. However, we found a similar level of increase (1.5-2 fold) in Arc 
malonyl-CoA by cerulenin compared to that seen following leptin treatment (compare Fig. 4B with Fig. 
3B). We thus assume that cerulenin treatment produced the same effect on CPT-1a activity as leptin 
treatment did. Together, our data indicate that malonyl-CoA inhibition of Arc CPT-1a is not required for 
the anorectic effects of either leptin or cerulenin.  
 
Changes in long-chain acyl-CoA's level in the Arc are dissociated from those in malonyl-CoA 
levels under fasting and refeeding conditions.   Under different nutritional states such as fasting and 
refeeding, circulating leptin level changes in tight association with that of hypothalamic malonyl-CoA level 
(9, 14). If LCFA-CoA’s act as downstream mediator of malonyl-CoA action in leptin's intracellular signaling 
pathways, the levels of LCFA-CoA's should also change in association with the level of malonyl-CoA. To 
assess this hypothesis, we examined the Arc levels of LCFA-CoA's and malonyl-CoA under fasting and 
refeeding conditions. Unexpectedly, we found that Arc LCFA-CoA’s levels were increased by fasting even 
though the malonyl-CoA level decreased (Fig. 5A), and these changes were reversed upon re-feeding 
(Fig. 5A). Thus, in the Arc, the changes in LCFA-CoA's levels appear to dissociate from those in malonyl-
CoA level under different feeding states.  It is known that CPT-1-mediated fatty acid β-oxidation activity in 
the brain is trivial as compared to the periphery (16). In determining the size of brain LCFA-CoA's pool, 
other actions/pathways such as exchange with the circulation, the action of acyl-CoA synthetase (ACS) 
and brain acyl-CoA hydrolase (BACH) play more prominent roles (Fig. 5B and ref. (16). Here, we showed 
that fasting elevated the fatty acid levels in the circulation while re-feeding brought down the elevated 
levels (Fig. 5C). Furthermore, the BACH activity was lowered by fasting and elevated to pre-fasting level 
following re-feeding (Fig. 5D). Although the physiological relevance of these changes is unclear, these 





CPT-1a, a key enzyme in regulating mitochondrial fatty acid β-oxidation, has been proposed to be a 
candidate for mediating hypothalamic malonyl-CoA's anorectic actions. In the CNS, as fatty acid β-
oxidation activity is trivial, malonyl-CoA-mediated regulation of CPT-1 acyltransferase activity is not as 
significant in the brain as it is in the periphery (16). Indeed, in our current and previous studies (6), we 
found no change of the Arc levels of either LCFA-CoA's (substrates of CPT-1a), or LC-AC's (products of 
CPT-1a), upon leptin administration under normal conditions. These results suggest that leptin treatment 
does not affect CPT-1 acyltransferase activity in the Arc. Thus, Arc CPT-1a may not be implicated in 
leptin’s central actions on feeding under normal conditions. In particular, our data indicate that CPT-1a is 
not a critical component of malonyl-CoA signaling mechanisms in leptin’s anorectic actions. Some 
potential mechanisms underlie this conclusion. First, due to the inherent heterogeneity of CNS cells (28), 
malonyl-CoA metabolism and CPT-1a expression might not take place in the same cells (31). Thus, the 
change of malonyl-CoA level in response to leptin may occur in a population of cells that does not 
express CPT-1a. Secondly, malonyl-CoA produced by the two isoforms of ACC (ACC-1 and ACC-2) has 
different effects on CPT-1a activity. Compared to ACC2, the ACC-1-associated malonyl-CoA does not 
significantly affect CPT-1a-mediated fatty acid β-oxidation (19). It should be noted that we have 
demonstrated leptin specifically activates ACC1 to increase malonyl-CoA level (6). It follows that malonyl-
CoA may not inhibit Arc CPT-1a in leptin's anorectic actions. Finally, due to the inherent nature of low 
activity, the CPT-1a in the Arc may not be subject to the regulation by malonyl-CoA particularly when 
malonyl-CoA is increased. Under physiological conditions, the already low activity of CPT-1a in the Arc 
may be resistant to a further inhibition by malonyl-CoA. Under artificial conditions such as when wild type 
CPT-1a is ectopically overexpressed, leptin treatment does inhibit CPT-1a activity and reduce LCFA-
CoA’s levels. However, the blockades of these changes fail to affect leptin’s anorectic actions. Therefore, 
in the Arc, malonyl-CoA inhibition of CPT-1a seems unlikely to play a key role in mediating leptin’s 
feeding actions. Our data also show that leptin’s effect on body weight is independent of malonyl-CoA-
mediated CPT-1a inhibition. Together with the results of food intake, we speculate that leptin’s action on 
body energy expenditure would also be independent of malonyl-CoA's inhibitory effect on CPT-1a. 
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However, a definitive conclusion requires direct measurement of energy expenditure in the experimental 
paradigm. 
 
There have been increasing concerns (16) with the hypothesis that inhibiting Arc CPT-1a with the ensuing 
increases of LCFA-CoA’s can produce anorectic effects (23, 24). Our results provide further evidence to 
support the notion that these biochemical events are not implicated in leptin's anorectic actions. In 
addition, particularly under acute experimental conditions (24), intracellular LCFA-CoA's levels may not 
go up following the treatment with long-chain fatty acids (16, 24). Moreover, a growing body of evidence 
now shows that accumulation of hypothalamic LCFA-CoA’s is indeed associated with increase in food 
intake, and increases in adiposity and body weight (3, 4, 25). Notably, ghrelin, an orexigenic factor that 
potently stimulates feeding, increases hypothalamic LCFA-CoA's levels while inhibits hypothalamic ACC, 
which reduces malonyl-CoA level (3). The observed increases in LCFA-CoA’s levels suggest that the 
action of LCFA-CoA's, at least in ghrelin’s hypothalamic pathways, can dissociate from that of malonyl-
CoA. In line with this prediction, we demonstrate a dissociation of the levels of LCFA-CoA's from that of 
malonyl-CoA under fasting and re-feeding conditions. It is also worth pointing out that Arc overexpression 
of acyl-CoA synthetase (ACS) raising LCFA-CoA’s levels does not induce the expected anorexigenic 
actions (personal communication with Dr. Jason Dyck, University of Alberta). Together, these data 
strongly challenge the proposed anorectic role of Arc LCFA-CoA’s, and they also argue against the view 
that LCFA-CoA’s can act as effectors of Arc malonyl-CoA-mediated anorectic actions.  
 
Further challenge to a role of CPT-1a and LCFA-CoA's as mediators of malonyl-CoA feeding action 
comes from the study using compound C89b, a CPT-1 activator (1). It was expected that C89b treatment, 
by activating CPT-1a and thus reducing LCFA-CoA’s levels, would stimulate food intake. Surprisingly, the 
study demonstrated that C89b induced the same feeding response, i.e. an inhibition, as the increase in 
Arc malonyl-CoA level (1). These C89b data also directly contradict the previous finding that CPT-1a 
inhibition (with ST1326) reduces feeding. Because opposing actions on the same targets produce similar 
feeding effects, these data further suggest that CPT-1a and LCFA-CoA’s are not implicated in the 
hypothalamic control of feeding. In support of this prediction, our results are also unfavorable for a 
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significant role of Arc CPT-1a per se in the CNS control of feeding and body weight. In our studies, we 
were unable to detect significant changes of either food intake or body weight gain following Arc-specific 
activation of CPT-1a. Furthermore, we demonstrated that CPT-1a activity (by measuring the levels of 
long-chain acylcarnitines) in the Arc was not significantly altered under either fasting or re-feeding 
condition (ad. lib. fed: 100 ± 17 %, fasted: 104 ± 14 %, re-fed: 112 ± 10 %). Taking these findings together, 
Arc CPT-1a is unlikely to play a direct and key role in the central controls of feeding and energy balance. 
 
The recent discovery of the brain-specific CPT-1 isoform, CPT-1c (26), may provide some insights into 
differential roles of CPT-1 isoforms in the central control of feeding and body energy balance. CPT-1c is 
structurally similar to CPT-1a and CPT-1b, but does not have an appreciable CPT acyltransferase activity 
(26, 30). Notably, CPT-1c has been implicated in the hypothalamic control of energy balance (30). Given 
that CPT-1c exhibits a high amino acid sequence similarity to the other CPT-1 members, those CPT-1a 
regulators (i.e. ST1326 and C89b) may have affected CPT-1c with the same pharmacological action, thus 
resulting in the same feeding effect. Furthermore, we anticipate that CPT-1c is an alternative downstream 
mediator in malonyl-CoA's anorectic signaling action. Indeed, our studies have provided evidence that 
CPT-1c is a downstream mediator of the malonyl-CoA action in leptin Arc anorectic signaling pathways 
(addressed in another manuscript). 
 
Perspectives and Significance 
 
Our data strongly suggest that the intracellular downstream pathways mediating Arc malonyl-CoA’s 
anorectic effects induced by leptin are independent of CPT-1a. Our study thus leaves open the possibility 
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Figure 1: M593S mutant of CPT-1a is insensitive to malonyl-CoA inhibition. 
Yeast extract (10µg of protein) of wild type CPT-1a or M593S mutant CPT-1a was incubated with 
increasing concentrations of malonyl-CoA, and the CPT-1 activities in the extract were measured (n=4-5).   
(B) The adenovirus (Ade) expressing the control (null, n=6), wild type CPT-1a (CPT-1a wt, n=6) or M593S 
mutant CPT-1a (CPT-1a mt, n=6) was administered into the arcuate nucleus (Arc). Two weeks following 
the administration of the viruses, the rats were euthanized. The individual hypothalamic nuclei tissues 
(Arc, VMN, LHA and PVN) were dissected from the brain sections and the CPT-1a protein levels were 
examined by Western blotting. Two representative blots from the Arc of each group are shown and the 
ratios of the band intensity of CPT-1a to that of β-actin were quantitated (n=6). * and **, vs. null, P<0.05.   
(C)  Two weeks following Arc administration of the adenoviruses encoding the null, CPT-1a wt and CPT-1 
mt (n=6), the CPT acyltransferase activities in the MBH encompassing the entire Arc and some VMN, 
LHA and the PVN were measured. The CPT-1a activities of individual VMN tissues were not measured. * 
and **, vs. null, P<0.05.   (D) Two weeks following the delivery of the viruses (encoding CPT-1a wt and 
CPT-1a mt), the rats were euthanized. The mediobasal hypothalamus (MBH) area containing the Arc was 
dissected and the crude mitochondrial fraction was prepared. Exogenous malonyl-CoA (50µM) was 
added to the mitochondrial preparation and CPT-1 activity assay was conducted (n=8).  The percentages 
of the activity inhibition by malonyl-CoA (compared to the assay without the addition of exogenous 









Figure 2: The increase of Arc malonyl-CoA is required in leptin’s anorectic actions. 
(A) The adenovirus encoding the malonyl-CoA decarboxylase (MCD, n=5) or eGFP (null, n=5) was 
administered into the Arc on day 0. Daily food intakes and daily body weights were monitored. The daily 
food intake before the virus injection was used as the baseline level. The differences between the daily 
food intake from day 1 through day 7 and the basal level are presented. The daily body weight from day 1 
through day 7 was compared to day 0 and the percentages of the body weight change are presented. 
Food intakes: * and **, vs. null, P<0.05; ***, vs. null, P=0.05.  Body weights: *, **, *** and ****, vs. null, 
P<0.05.   (B) After one week following Arc delivery of the adenoviruses (MCD, n=5; null, n=5), the rats 
were euthanized. The MCD activities in individual hypothalamic nuclei (Arc, VMN, LHA and PVN) were 
measured. The MCD activities from the Arc (n=5) and the VMN (n=5) are shown. *, vs. null, P<0.05.   (C) 
The rats were subject to the similar procedures as described in (B). The malonyl-CoA levels (n=3-4) in the 
Arc were measured. *, vs. null, P<0.05.   (D) After one week following the virus delivery, a bolus injection 
of leptin (15 µg, in PBS) was given by ICV before the dark cycle. Then, the food intakes at 3h after the 
dark onset were monitored (n=6-9). *, vs. null/PBS, P<0.05;  **, vs. MCD/PBS, P<0.05;  †, vs. null/leptin, 
P<0.05.  Malonyl-CoA levels in the Arc were measured and the percentages of the increase of malonyl-














Figure 3: Blocking malonyl-CoA inhibition of CPT-1 acyltransferase activity  does not affect the 
anorectic action of leptin. 
(A) During the second week following the Arc administration of Ade-CPT-1a wt, Ade-CPT-1a mt or Ade-
null, a bolus injection of leptin (15 μg in PBS) was given by ICV to the rats before the dark cycle. 
Overnight food intake and body weight were monitored (n=6). The values from the rat having a targeted 
Arc overexpression of CPT-1a and an increase of CPT acyltransferase activity were included in the data 
analysis. *, vs. null/PBS, P<0.05; **, vs. CPT-1a wt/PBS, P<0.05; ***, vs. CPT-1a mt/PBS, P<0.05.   (B,C 
and D) After one week following the Arc delivery of the adenoviruses (CPT-1a wt, CPT-1a mt and null), a 
bolus injection of leptin (15 μg in PBS) was given by ICV to the rats. The Arc levels (at 3h after ICV 
injection) of the malonyl-CoA (B, n=5-7), long-chain acylcarnitines (C, n=5-6) and the long-chain acyl-
CoA’s (D, n=5-8) were measured. NS: the differences between CPT-1a mt/PBS and CPT-1a mt/leptin are 
not significant.  (B) *, vs. null/PBS, P<0.05; **, vs. CPT-1a wt/PBS, P<0.05; ***, vs. CPT-1a mt/PBS, 
P<0.05.  (C) *, CPT-1a wt/PBS vs. null/PBS, P<0.05; **, CPT-1a mt/PBS vs. null/PBS, P<0.05; †, CPT-1a 
wt/leptin vs. CPT-1a wt/PBS, P<0.05; NS, CPT-1a mt/leptin vs. CPT-1a mt/PBS, not significant.  (D) *, 
CPT-1a wt/PBS vs. null/PBS, P<0.05; **, CPT-1a mt/PBS vs. null/PBS, P<0.05; †, CPT-1a wt/leptin vs. 
CPT-1a wt/PBS, P<0.05; NS, CPT-1a mt/leptin vs. CPT-1a mt/PBS, not significant.  
 
 










Figure 4: Blocking malonyl-CoA inhibition of CPT-1 acyltransferase activity does not affect the 
anorectic action of cerulenin. 
(A) Ade-MCD or Ade-null was delivered into the Arc of rats. After one week following Arc delivery of the 
adenoviruses, a bolus injection of cerulenin (125µg, in 25% DMSO) was given by ICV before the dark 
cycle. Then the malonyl-CoA levels in the Arc were measured. The percentages of the increase of the 
malonyl-CoA level by cerulenin (as compared to 25% DMSO) are shown (n=6-7).  Following ICV injection 
of cerulenin, the food intakes at 3h after the dark onset and the overnight (24h) body weight changes 
were also monitored (n=6-7). *, P<0.05, vs. null.   (B) Ade-CPT-1a wt, Ade-CPT-1a mt or Ade-null was 
delivered into the Arc of rats. After one week following Arc delivery of the adenoviruses, a bolus injection 
of cerulenin (125µg, in 25% DMSO) was given by ICV before the dark cycle and overnight food intake 
and overnight body weight were monitored (n=8-10). Malonyl-CoA levels in the Arc were also measured 
and the percentages of the increase of the malonyl-CoA level by cerulenin (as compared to 25% DMSO) 
are shown (n=8-10). *, vs. null/vehicle, P<0.05; **, vs. CPT-1a wt/vehicle, P<0.05; ***, vs. CPT-1a 















Figure 5: The changes of long-chain acyl-CoA’s levels in the Arc are dissociated from the changes 
of malonyl-CoA levels under fasting and re-feeding conditions. 
(A) Some rats were fasted for 48h (fasted, n=9), and the other rats were re-fed for 3h after being fasted 
for 48h (re-fed, n=6). Arc levels of long-chain fatty acyl-CoA’s and malonyl-CoA were measured. Ad. lib. 
fed (n=6) was used as the control.  *, fasted vs. ad. lib. fed, P<0.05; **, re-fed vs. fasted, P<0.05.   (B) A 
schematic diagram of the metabolism of brain cellular long-chain fatty acyl-CoA’s (LCFA-CoA’s) is shown. 
Intracellular long-chain fatty acid (LCFA) either synthesized de novo or transported from the circulation is 
esterified by acyl-CoA synthetase (ACS) to form LCFA-CoA’s. Hydrolysis by acyl-CoA hydrolase and the 
CPT-1a-mediated mitochondrial β-oxidation are two pathways that lower the cellular LCFA-CoA’s levels. 
In the brain, acyl-CoA hydrolase (BACH) action plays a major role, while the mitochondrial β-oxidation is 
a minor pathway, in controlling the cellular LCFA-CoA’s levels.   (C) The rats were subjected to the fasting 
and re-feeding procedure as described in (A). The plasma levels of free fatty acid were measured (n=5). 
Ad. lib. fed was used as the control. *, fasted vs. ad. lib. fed, P<0.05; **, re-fed vs. fasted, P<0.05.   (D) 
Some rats were fasted for one overnight (fasted, n=5) and the other rats were re-fed for 3h after being 
fasted for two overnights (re-fed, n=3). Arc acyl-CoA hydrolase activities were measured. Note: the acyl-
CoA hydrolase activity levels between 24h-fasting and 48h-fasting are comparable. *, vs. ad. lib. fed, 
P<0.05. 
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Arc acyl-CoA hydrolase activities under different feeding states D 
(Figure 5) 
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